That's a good point, but if you look at RedChip's valuations of PAA's assets you wouldn't call them extravagant, especially when you look at their list of comparable companies.
Respected Florida based US research house Redchip, has re-rated ASX listed cancer drug hopeful Pharm, page-14
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.5¢ |
Change
0.010(4.65%) |
Mkt cap ! $109.4M | |||
| Open | High | Low | Value | Volume |
| 21.5¢ | 22.5¢ | 21.5¢ | $344.1K | 1.553M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 24000 | 22.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.0¢ | 247055 | 7 |
View Market Depth
| Last trade - 11.46am 14/10/2024 (20 minute delay) ? |
| PAA (ASX) Chart |